These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Hashimoto K; Nii T; Sumitani H; Yokoyama M; Miyamoto S; Mihashi Y; Nagata Y; Matsuki T; Tsujino K; Miki K; Kida H Infect Drug Resist; 2023; 16():6629-6634. PubMed ID: 37840829 [TBL] [Abstract][Full Text] [Related]
13. Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Morita A; Namkoong H; Yagi K; Asakura T; Hosoya M; Tanaka H; Lee H; Ogawa T; Kusumoto T; Azekawa S; Nakagawara K; Kamata H; Ishii M; Fukunaga K; Ozawa H; Hasegawa N Infect Drug Resist; 2022; 15():4001-4011. PubMed ID: 35924016 [TBL] [Abstract][Full Text] [Related]
14. Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. Shirley M Drugs; 2019 May; 79(7):791. PubMed ID: 30941606 [TBL] [Abstract][Full Text] [Related]
15. Nontuberculous mycobacterial lung disease caused by van Ingen J; Obradovic M; Hassan M; Lesher B; Hart E; Chatterjee A; Daley CL Expert Rev Respir Med; 2021 Nov; 15(11):1387-1401. PubMed ID: 34612115 [TBL] [Abstract][Full Text] [Related]
16. Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use. Hoy SM Clin Drug Investig; 2021 Jun; 41(6):591. PubMed ID: 33880719 [No Abstract] [Full Text] [Related]
17. Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease. Kim BG; Kim SR; Jhun BW Tuberc Respir Dis (Seoul); 2024 Apr; 87(2):202-205. PubMed ID: 37726944 [No Abstract] [Full Text] [Related]
18. ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland? Daley CL; Olivier KN Am J Respir Crit Care Med; 2018 Dec; 198(12):1473-1475. PubMed ID: 30365392 [No Abstract] [Full Text] [Related]
19. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870 [TBL] [Abstract][Full Text] [Related]
20. Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey. Swenson C; Lapinel NC; Ali J Open Forum Infect Dis; 2020 Apr; 7(4):ofaa079. PubMed ID: 32322600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]